Krsnaa Diagnostics delivers strong performance in H1FY22

Revenue up by 19 per cent, EBITDA up by 76 per cent and PAT without CCPS is up by 167 per cent on a YoY basis

Krsnaa Diagnostics Ltd is one of India’s fastest growing diagnostic service providers, both in radiology and pathology. The company announced the results for first six months ending September 30, 2021, following its listing on the stock exchanges on August 16, 2021.

H1 FY2022 Performance Highlights - 

• Revenue from operations of Rs. 241 crores, up 19 per cent YoY

• EBITDA* of Rs. 74 crores, up 76 per cent YoY

• EBITDA* Margins increased to 30.9 per cent in H1FY22 as compared to 20.9 per cent in H1FY21

• Profit After Tax without CCPS of Rs. 34 crore, up by 167 per cent with margins of 13.8 per cent

• Net cash position of Rs. 326 crores at the end of September 2021

• Core business i.e. radiology and pathology registered a revenue increase of 143 per cent YoY, which was partially offset by a decline of 75 per cent during Covid-19

• Core business contribution was 89 per cent whereas Covid-19 business contributed 11 per cent to the total revenues in H1 FY22

* EBITDA is excluding CSR and ESOP expenses

Krsnaa Diagnostics Ltd. is India’s fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 14 states with 1800+ centres across the country.  Its mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and commitment towards the same is what defines and differentiates it. The company delivers clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for its patients in any corner of the country.

On Tuesday, the share of Krsnaa Diagnostics has opened in red being 6.2 per cent down and trading at Rs 751.65 per share on BSE.